AKBA stock news

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that its President and Chief Executive Officer, John P. Butler, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 9:30 a.m. PT in San Francisco. A live webcast and replay of Akebia’s presentation and associated Q&A will Read more
Akebia Therapeutics Inc (NASDAQ: AKBA ) shares are up 49.6% in the past week, but at least one larger option trader is betting on more upside for the biotech company in the next month. The Trades On Tuesday morning, Benzinga Pro subscribers received an option alert related to an unusually large Akebia trade. At 8:52 a.m., a trader bought 606 Akebia call options with a $5 strike price expiring on Dec. 20 near the ask price at 45.1 cents. The trade represented a $27,330 bullish bet. Why It’s Important Even traders who stick exclusively to stocks often monitor option market activity closely for unusually large trades. Given the relative complexity of the options market, large options traders are typically considered to be more sophisticated than the average stock trader. Many of these large options traders are wealthy individuals or institutions who may have unique information or theses related to the … Full story available on Benzinga.com Read more
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced its executives will participate in the following investor conferences: Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019, at 8:30 a.m. ET in New York City, New York. Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019, at Read more
DUBLIN--(BUSINESS WIRE)--The "Anemia And Other Blood Disorder Drugs Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global anemia and other blood disorder drugs market was valued at about $19.7 billion in 2018 and is expected to grow to $29.37 billion at a CAGR of 10.5% through 2022. Major players in the market are Amgen, GlaxoSmithKline, Akebia therapeutics, Bayer and Pfizer. North America was the largest region in the anemia and other blood disorder Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ). Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. Read more
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 24.32% and -2.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today reported financial results for the third quarter ended September 30, 2019. The Company will host a conference call today, Tuesday, November 12, 2019, at 9:00 a.m. Eastern Time to discuss its third quarter 2019 financial results and recent business highlights. Akebia also announced th Read more
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive Read more
Who Has Spent The Most Dollars Lobbying Washington In 2019? Authored by Karl Evers-Hillstrom via OpenSecrets.org The pharmaceutical industry is holding on to its title as the top lobbying force in Washington amid pressure from lawmakers at all ends of the ideological spectrum. Drugmakers have spent more than $129 million through September, slightly down from nearly $133 million at this time last year , but still far more than any other industry. The larger pharmaceutical/health products industry, which includes medical devices and dietary supplement companies along with drugmakers, spent $228 million through the third quarter of 2019 , a record-breaking pace that is up $10 million from this time last year. House Democrats recently advanced legislation that allows the federal government to negotiate the price of drugs that lack generic equivalents. The bill passed the House Ways and Means Committee this week without a number of amendments proposed by progressive Democrats who argued the bill isn’t strong enough. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S. Read more
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc. Read more
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH )(announced a deal to buy University of Minnesota startup B-MoGen technology) Blueprint Medicines Corp (NASDAQ: BPMC ) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 6) Acorda Therapeutics Inc (NASDAQ: ACOR ) Aduro BioTech Inc (NASDAQ: ADRO ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Aptinyx Inc (NASDAQ: APTX ) Axovant Gene Therapies Ltd (NASDAQ: AXGT )(reported six-month follow-up data from the first dose cohort in the Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson's disease and also issued pipeline update) Bellicum Pharmaceuticals (NASDAQ: BLCM ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Cellectis SA (NASDAQ: CLLS ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evolent Health Inc (NYSE: EVH ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Hemispherx BioPharma, Inc (NYSE: HEB ) IMMURON LTD/S ADR (NASDAQ: IMRN ) IMMUTEP LTD/S ADR (NASDAQ: IMMP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) Neuronetics Inc (NASDAQ: STIM ) Puma Biotechnology Inc (NASDAQ: PBYI ) Seres Therapeutics Inc (NASDAQ: … Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT